AU2022223437A1 - Combination of raf inhibitor and mek inhibitor - Google Patents

Combination of raf inhibitor and mek inhibitor Download PDF

Info

Publication number
AU2022223437A1
AU2022223437A1 AU2022223437A AU2022223437A AU2022223437A1 AU 2022223437 A1 AU2022223437 A1 AU 2022223437A1 AU 2022223437 A AU2022223437 A AU 2022223437A AU 2022223437 A AU2022223437 A AU 2022223437A AU 2022223437 A1 AU2022223437 A1 AU 2022223437A1
Authority
AU
Australia
Prior art keywords
braf
subject
cancer
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022223437A
Other languages
English (en)
Inventor
Samuel C. BLACKMAN
Eleni Venetsanakos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Day One Biopharmaceuticals Inc
Original Assignee
Day One Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Day One Biopharmaceuticals Inc filed Critical Day One Biopharmaceuticals Inc
Publication of AU2022223437A1 publication Critical patent/AU2022223437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022223437A 2021-02-19 2022-02-18 Combination of raf inhibitor and mek inhibitor Abandoned AU2022223437A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163151425P 2021-02-19 2021-02-19
US63/151,425 2021-02-19
US202163173158P 2021-04-09 2021-04-09
US63/173,158 2021-04-09
PCT/US2022/016962 WO2022178244A1 (en) 2021-02-19 2022-02-18 Combination of raf inhibitor and mek inhibitor

Publications (1)

Publication Number Publication Date
AU2022223437A1 true AU2022223437A1 (en) 2023-09-07

Family

ID=82931723

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022223437A Abandoned AU2022223437A1 (en) 2021-02-19 2022-02-18 Combination of raf inhibitor and mek inhibitor

Country Status (10)

Country Link
US (1) US20240058338A1 (https=)
EP (1) EP4294400A4 (https=)
JP (1) JP2024507221A (https=)
KR (1) KR20230147136A (https=)
AU (1) AU2022223437A1 (https=)
CA (1) CA3211167A1 (https=)
IL (1) IL305250A (https=)
MX (1) MX2023009642A (https=)
WO (1) WO2022178244A1 (https=)
ZA (1) ZA202307921B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4408430A4 (en) * 2021-10-01 2025-07-30 Day One Biopharmaceuticals Inc RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMORS WITH GENE FUSIONS
WO2025106686A1 (en) * 2023-11-15 2025-05-22 Day One Biopharmaceuticals, Inc. Methods of treating pediatric low-grade glioma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
WO2016025648A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a raf inhibitor and related methods
AU2018329925B2 (en) * 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer

Also Published As

Publication number Publication date
ZA202307921B (en) 2024-04-24
EP4294400A1 (en) 2023-12-27
WO2022178244A1 (en) 2022-08-25
MX2023009642A (es) 2023-10-16
EP4294400A4 (en) 2025-01-01
US20240058338A1 (en) 2024-02-22
IL305250A (en) 2023-10-01
CA3211167A1 (en) 2022-08-25
KR20230147136A (ko) 2023-10-20
JP2024507221A (ja) 2024-02-16

Similar Documents

Publication Publication Date Title
US8853277B2 (en) Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
CN107949387B (zh) 用谷氨酰胺酶抑制剂治疗肺癌
US20240058338A1 (en) Combination of raf inhibitor and mek inhibitor
JP2018526324A (ja) がんの診断および処置の方法
JP2016522160A (ja) 併用療法
JP2020517696A (ja) Ｈｅｒ２陽性がんの処置
TW202221118A (zh) 複製壓力路徑劑組合物及治療癌症之方法
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
BR112021012132A2 (pt) Derivados de quinolina para uso no tratamento ou prevenção de câncer
BR112021007237A2 (pt) métodos para o tratamento de uma vasculopatia em um indivíduo e para o tratamento de um transtorno do tecido conjuntivo em um indivíduo, kit, e, composição farmacêutica para o tratamento de uma vasculopatia
Shim et al. Intraoperative multimodal analgesic bundle containing dexmedetomidine and ketorolac may improve analgesia after robot-assisted prostatectomy in patients receiving rectus sheath blocks
EP4213852A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2025157287A1 (zh) 包含prmt5抑制剂和egfr抑制剂的药物组合物
CA2814828C (en) Method of treatment for mental disorders
CN116490177A (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
EA015933B1 (ru) Лечение детских опухолей
JP6267619B2 (ja) 慢性骨髄性白血病の治療用組成物
CN117177754A (zh) Raf抑制剂和mek抑制剂的组合
EP4110331B1 (en) Methods of treating dlbcl using btk inhibitors and combinations thereof
JP2015512416A (ja) 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
Potapenko et al. CRIZOTINIB IN TREATMENT OF ATYPICAL ALK-REARRANGED HISTIOCYTE-RICH TUMOR. CASE REPORT
Shah et al. PP01. 05 Targeting MUC16-Mediated KRASi Resistance in NSCLC
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
JP2023178473A (ja) 小児患者のがんの治療方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period